Vor Biopharma (VOR) Equity Average (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Equity Average data on file, last reported at -$157.4 million in Q1 2026.

• Equity Average for Q1 2026 came in at -$157.4 million, down 928.72% year-over-year; the trailing twelve-month figure through Mar 2026 was -$157.4 million (down 928.72% YoY), and the FY2025 annual result was -$130.5 million, down 582.75% from the prior year.
• Equity Average climbed to -$157.4 million in Q1 2026 per VOR's latest filing, from -$1.2 billion in the prior quarter.
• Over five years, Equity Average peaked at $240.4 million in Q1 2023 and troughed at -$1.9 billion in Q3 2025.
• A 5-year average of -$121.2 million and a median of $136.9 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average surged 97.34% in 2022, then sank 9979.71% in 2025.
• A 5-year view of Equity Average shows it stood at $204.7 million in 2022, then decreased by 20.48% to $162.8 million in 2023, then tumbled by 107.28% to -$11.9 million in 2024, then slumped by 9979.71% to -$1.2 billion in 2025, then soared by 86.83% to -$157.4 million in 2026.
• Business Quant data shows VOR's Equity Average at -$157.4 million in Q1 2026, -$1.2 billion in Q4 2025, and -$1.9 billion in Q3 2025.